A global leader in the diagnostics of serum protein with a superior technology in electrophoresis.
Sebia is a research-driven company covering several pathologies including multiple myeloma, diabetes (HbA1c) and haemoglobin deficiencies. Montagu originally acquired the business in 2006 and invested for a second time in 2014.
Revenue growth 2014-2018
Instruments in installed base
Countries products sold into
Between 2014 and 2018, we supported Sebia:
Sebia was sold to a consortium of long term investors: Caisse de dépôt et placement du Québec (CDPQ), Téthys and CVC's long term fund.